We are an early stage drug development company focusing on pathologies showing an aberrant up-regulation of the PI3K/Akt/mTOR pathway including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (renal and pulmonary fibrosis), CNS (epilepsy and neurodegenerative diseases), antiviral (HIV/AIDS) and skin diseases (psoriasis, atopic dermatitis and photodamage/wrinkling).

Paloma owns the intellectual property relating to a series of novel, proprietary, small molecule drugs created through an integrated design platform incorporating proprietary, customized and industry standard computational tools that has therapeutic potential for the treatment of the foregoing diseases.

21-24 April 2013 - Paloma Pharmaceuticals presents at the Institute for International Research USA, 22nd Partnerships in Clinical Trials meeting, "Lessons Learned from a Successful Virtual Pharma Company: Paloma Pharmaceuticals Case Study" and "Moderator - The Frontier of Innovation: Takeaways for Big Pharma", Orlando, Fl


22 February 2013
Paloma Pharmaceuticals publishes paper entitled, "Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2" in International Journal of Cancer, February 2013.